Paper Details

  1. Home
  2. Paper Details

ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.

Author: , ChenBingshu E, ConnorsJoseph M, CrumpMichael, DarA Rashid, DjurfeldtMarina S, GospodarowiczMary K, HorningSandra J, MeyerRalph M, PearceyRobert G, ShepherdLois E, ShustikChaim, StewartDouglas A, WellsWoodrow A, WinterJane N

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Among patients with Hodgkin’s lymphoma, ABVD chemotherapy alone was associated with a higher rate of overall survival (94%) compared to treatment with subtotal nodal radiation therapy (87%). The higher survival rate was due to a lower rate of death from other causes.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Chemotherapy plus radiation treatment is effective in controlling stage IA or IIA nonbulky Hodgkin's lymphoma in 90% of patients but is associated with late treatment-related deaths. Chemotherapy alone may improve survival because it is associated with fewer late deaths. METHODS: We ran...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/22149921

データ提供：米国国立医学図書館（NLM）

ABVD Alone Versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma

The field of [oncology] constantly seeks to [optimize treatment strategies] for [Hodgkin's lymphoma]. This study investigates the [efficacy and safety] of [ABVD chemotherapy alone] versus [radiation-based therapy] in patients with [limited-stage Hodgkin's lymphoma]. Through a [randomized clinical trial], the researchers compared the [outcomes] of these two treatment approaches. Their findings highlight the [potential advantages of ABVD chemotherapy alone] in terms of [overall survival] and [reduced late treatment-related deaths], offering valuable insights for [treatment decision-making] in [limited-stage Hodgkin's lymphoma].

ABVD Chemotherapy Alone: A Promising Option for Limited-Stage Hodgkin's Lymphoma

The study's results suggest that [ABVD chemotherapy alone] may be a [more effective treatment option] for [limited-stage Hodgkin's lymphoma], leading to a [higher rate of overall survival] compared to [radiation-based therapy]. This is particularly significant due to the [reduced risk of late treatment-related deaths] associated with [ABVD alone].

Personalized Treatment Approaches in Hodgkin's Lymphoma

This study emphasizes the importance of [personalizing treatment approaches] for [Hodgkin's lymphoma], considering [individual patient factors, disease stage, and risk profile]. It underscores the need for [open communication and collaboration between patients and clinicians] to make [informed treatment decisions] that maximize [long-term survival and quality of life].

Dr.Camel's Conclusion

Just as a camel navigates the vast desert, researchers are traversing the complex landscape of Hodgkin's lymphoma treatment. This study provides a valuable compass, guiding clinicians toward the most effective treatment approaches for limited-stage Hodgkin's lymphoma. By understanding the potential benefits and limitations of different therapies, we can empower patients to make informed decisions and achieve optimal outcomes in their journey toward recovery.

Date :
  1. Date Completed 2012-02-08
  2. Date Revised 2022-03-10
Further Info :

Pubmed ID

22149921

DOI: Digital Object Identifier

NIHMS356901

Related Literature

Article Analysis
・Effective treatment of lymphoma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.